Aevice Health Receives Singapore HSA Approval for First Smart Wearable Stethoscope in Singapore
Singapore, 29 March 2023 – Aevice Health, a Singapore-based MedTech company that specializes in developing remote respiratory monitoring solutions, today announced that its flagship medical device, the AeviceMD Monitoring System, has received approval from the Health Sciences Authority of Singapore (HSA). The award-winning patient management platform, powered by a smart wearable stethoscope, is the first of its kind to be made available in Singapore.
The AeviceMD Monitoring System’s wearable stethoscope is one of the smallest globally that can detect abnormal breath sounds, such as wheezing, and monitor vital signs including heart rate and respiratory rate. The device, which is approved for use in patients three years and above, has a unique form factor that allows for continuous and comfortable monitoring across a wide spectrum of ages from young children to the elderly, where respiratory diseases are more prevalent.
Approved for use in both clinical and home settings, the AeviceMD Monitoring System is versatile, providing healthcare professionals with the opportunity to be flexible with the deployment of the device. In-hospital monitoring, hospital-at-home monitoring, and remote monitoring to complement telehealth are just some of the potential use cases.
Chronic respiratory disease affects over 545 million people worldwide and is one of the leading causes of mortality. Asthma and COPD (Chronic Obstructive Pulmonary Disease), which are prevalent in Singapore and many other countries, contribute significantly
to hospital emergency department (ED) visits and readmissions. Early detection of exacerbations can prevent many of these hospitalizations.
The AeviceMD Monitoring System continuously monitors digital biomarkers of interest, providing healthcare professionals with an overview of the patient’s lung health to track progress over time. Patients, who are at risk of exacerbations, can be identified early to prevent readmissions or ED visits.
Adrian Ang, Chief Executive Officer of Aevice Health, said, “This is a momentous milestone for the company and a timely achievement as our pipeline of partnerships in Singapore grows. We are excited to leverage Singapore’s strategic presence in Asia as a medical hub to bring this novel technology into new markets where there is a high prevalence of respiratory diseases.”
With the approval of the AeviceMD Monitoring System, Aevice Health is well-positioned to expand its reach and provide much-needed respiratory monitoring solutions to patients in Singapore and beyond.
About Aevice Health
Aevice Health Pte Ltd is a MedTech company at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges.
The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the Aevice analytical platform.
In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives. More information about the company can be found at www.aevice.com.
For media enquiries, please contact:
Aevice Health Pte Ltd